CLINUVEL PHARMACEUTICALS LIMITED - Announcements

0.57%

$12.15

Market Cap $600.4M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

CUV	Update - Notification of buy-back - CUV		06/05/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		03/05/24	15.7KB	Share
CUV	Syd Capital Markets Briefing Presentation		01/05/24	4.01MB	Share
CUV	SCENESSE European Orphan Drug Designation for XP		29/04/24	88.75KB	Share
CUV	Notification of cessation of securities - CUV		29/04/24	12.86KB	Share
CUV	Update - Notification of buy-back - CUV		29/04/24	15.7KB	Share
CUV	Ceasing to be a substantial holder		26/04/24	856.04KB	Share
CUV	CLINUVEL expands global leadership team		22/04/24	76.98KB	Share
CUV	Change to executive management		15/04/24	63.29KB	Share
CUV	Update - Notification of buy-back - CUV		12/04/24	15.7KB	Share
CUV	Update - Notification of buy-back - CUV		10/04/24	15.69KB	Share
CUV	Update - Notification of buy-back - CUV		09/04/24	15.68KB	Share
CUV	Becoming a substantial holder		09/04/24	1.22MB	Share
CUV	Notification of cessation of securities - CUV		04/04/24	12.69KB	Share
CUV	CLINUVEL Newsletter II - March 2024		20/03/24	257.3KB	Share
CUV	Update - Notification of buy-back - CUV		18/03/24	13.65KB	Share
CUV	Notification of buy-back - CUV		14/03/24	13.06KB	Share
CUV	CLINUVEL initiates on market share buy-back program	PRICE SENSITIVE	14/03/24	89.87KB	Share
CUV	New case of SCENESSE efficacy in vitiligo presented at AAD	PRICE SENSITIVE	11/03/24	362.39KB	Share
CUV	SCENESSE Presented at American Academy of Dermatology		08/03/24	74.91KB	Share
CUV	Ceasing to be a substantial holder		05/03/24	1.12MB	Share
CUV	SCENESSE provides photoprotection in variegate porphyria	PRICE SENSITIVE	04/03/24	195.58KB	Share
CUV	Becoming a substantial holder		28/02/24	1.69MB	Share
CUV	Final Director's Interest Notice		27/02/24	188.5KB	Share
CUV	Half Year Results Webinar Recording		23/02/24	58.64KB	Share
CUV	CLINUVEL Delivers Increased Revenues, Solid Earnings		22/02/24	107.14KB	Share
CUV	CUV Appendix 4D Half Year Report	PRICE SENSITIVE	22/02/24	570.89KB	Share
CUV	Director Resignation		21/02/24	67.94KB	Share
CUV	CEO Letter to Shareholders		16/02/24	103.23KB	Share
CUV	Half Year Results Investor Webinar		16/02/24	59.78KB	Share
CUV	Change in substantial holding		31/01/24	1.58MB	Share
CUV	CLINUVEL Newsletter 1 - January 2024		16/01/24	256.64KB	Share
CUV	Chair Elect Letter		14/12/23	106.04KB	Share
CUV	Change to Registered Office		07/12/23	129.35KB	Share
CUV	Notification of cessation of securities - CUV		27/11/23	21.49KB	Share
CUV	Change of Director's Interest Notice		27/11/23	526.02KB	Share
CUV	Application for quotation of securities - CUV		27/11/23	25.55KB	Share
CUV	CLINUVEL Newsletter V - November 2023		24/11/23	481.47KB	Share
CUV	Sydney Vitiligo Presentation		10/11/23	874.94KB	Share
CUV	Final Director's Interest Notice		02/11/23	190.98KB	Share
CUV	CLINUVEL Appoints New Chair		31/10/23	135.75KB	Share
CUV	Results of Meeting		31/10/23	276.04KB	Share
CUV	CEO Presentation AGM		31/10/23	1.94MB	Share
CUV	Chair's Address		31/10/23	160.97KB	Share
CUV	CLINUVEL starts global Phase III vitiligo study		18/10/23	233.67KB	Share
CUV	CLINUVEL Newsletter IV - October 2023		06/10/23	245.17KB	Share
CUV	Board Changes after AGM		29/09/23	141.26KB	Share
CUV	Notice of Annual General Meeting/Proxy Form		29/09/23	577.45KB	Share
CUV	Change of Director's Interest Notice		20/09/23	321.36KB	Share
CUV	CEO Letter to Shareholders		19/09/23	192.64KB	Share
CUV	CLINUVEL Confirms AGM Date		13/09/23	117.29KB	Share
CUV	CLINUVEL Vitiligo Expert Panel		12/09/23	217.38KB	Share
CUV	SCENESSE in Adolescent EPP Study		05/09/23	228.91KB	Share
CUV	CLINUVEL Investor Webinar Transcript		30/08/23	895.6KB	Share
CUV	Appendix 4G and Corporate Governance Statement		29/08/23	579.18KB	Share
CUV	CLINUVEL delivering increases in annual revenue, profit		29/08/23	271.69KB	Share
CUV	Dividend/Distribution - CUV		29/08/23	22.38KB	Share
CUV	Appendix 4E and Annual Report to Shareholders 2023	PRICE SENSITIVE	29/08/23	12.68MB	Share
CUV	Annual Results Investor Webinar - time		28/08/23	131.05KB	Share
CUV	Technical Note - CUV151 results DNA Damage		15/08/23	365.52KB	Share
CUV	afamelanotide reduces DNA damage in healthy population		15/08/23	203.48KB	Share
CUV	SCENESSE applied under 5 year US Veterans Affairs contract		26/07/23	140.08KB	Share
CUV	CLINUVEL secures IP for melanocortins to treat CNS disorders		14/07/23	641.45KB	Share
CUV	Notification regarding unquoted securities - CUV		30/06/23	25.38KB	Share
CUV	Two Grounds of Appeal Upheld by NICE Panel		30/06/23	112.15KB	Share
CUV	Notification of cessation of securities - CUV		29/06/23	21.48KB	Share
CUV	Presentation - Melbourne Twilight Briefing		29/06/23	1.08MB	Share
CUV	Change of Director's Interest Notice		28/06/23	313.22KB	Share
CUV	CLINUVEL Newsletter III - June 2023		26/06/23	303.33KB	Share
CUV	Strategic Update VI		01/06/23	1.84MB	Share
CUV	PRENUMBRA administered to moderate & severe stroke patients		09/05/23	165.07KB	Share
CUV	Expansion of global porphyria programs		01/05/23	136.22KB	Share
CUV	CLINUVEL Newsletter II - April 2023		05/04/23	425.3KB	Share
CUV	Investor Presentation - NYC Nasdaq Event		30/03/23	4.12MB	Share
CUV	Technical Note - CUV803 Study and AIS		20/03/23	444.01KB	Share
CUV	First stroke patient treated with PRENUMBRA Instant		20/03/23	271.53KB	Share
CUV	DNA Repair data presented at AAD Meeting		17/03/23	119.77KB	Share
CUV	Statement on Silicon Valley Bank		13/03/23	89.95KB	Share
CUV	Proposed issue of securities - CUV		10/03/23	24.54KB	Share
CUV	Commercial Update SCENESSE		09/03/23	127.84KB	Share
CUV	Relief from Quarterly Reporting		02/03/23	82.33KB	Share
CUV	CLINUVEL launches first dermatocosmetic product		01/03/23	254.92KB	Share
CUV	Proposed issue of securities - CUV		28/02/23	24.53KB	Share
CUV	Global SCENESSE demand drives increased revenues, earnings		24/02/23	165.94KB	Share
CUV	CUV Appendix 4D Half Year Report	PRICE SENSITIVE	24/02/23	874.85KB	Share
CUV	PRENUMBRA formulation completed for clinical trial use		15/02/23	257.84KB	Share
CUV	Chair's Letter		09/02/23	215.25KB	Share
CUV	Technical note - CUV151 results		02/02/23	370.66KB	Share
CUV	Afamelanotide reduces UV skin damage in a healthy population		02/02/23	168.07KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	229.38KB	Share
CUV	NEURACTHEL manufacturing processes advance		23/01/23	359.1KB	Share
CUV	Technical Note - Xeroderma Pigmentosum		16/01/23	609.83KB	Share
CUV	afamelanotide Reduces DNA Photodamage in XP		16/01/23	333.77KB	Share
CUV	CLINUVEL Newsletter I - January 2023		10/01/23	510.39KB	Share
CUV	CLINUVEL Newsletter VI - December 2022		23/12/22	246.06KB	Share
CUV	Notification of cessation of securities - CUV		21/12/22	21.48KB	Share
CUV	Presentation - Jefferies London Healthcare Conference		17/11/22	3.31MB	Share
CUV	CLINUVEL Newsletter V - November 2022		09/11/22	546.94KB	Share
CUV	Change of Director's Interest Notice		07/11/22	216.26KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report Re-issued	PRICE SENSITIVE	31/10/22	348.75KB	Share

CUV Update - Notification of buy-back - CUV
06/05/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
03/05/24		15.7KB	Share
CUV Syd Capital Markets Briefing Presentation
01/05/24		4.01MB	Share
CUV SCENESSE European Orphan Drug Designation for XP
29/04/24		88.75KB	Share
CUV Notification of cessation of securities - CUV
29/04/24		12.86KB	Share
CUV Update - Notification of buy-back - CUV
29/04/24		15.7KB	Share
CUV Ceasing to be a substantial holder
26/04/24		856.04KB	Share
CUV CLINUVEL expands global leadership team
22/04/24		76.98KB	Share
CUV Change to executive management
15/04/24		63.29KB	Share
CUV Update - Notification of buy-back - CUV
12/04/24		15.7KB	Share
CUV Update - Notification of buy-back - CUV
10/04/24		15.69KB	Share
CUV Update - Notification of buy-back - CUV
09/04/24		15.68KB	Share
CUV Becoming a substantial holder
09/04/24		1.22MB	Share
CUV Notification of cessation of securities - CUV
04/04/24		12.69KB	Share
CUV CLINUVEL Newsletter II - March 2024
20/03/24		257.3KB	Share
CUV Update - Notification of buy-back - CUV
18/03/24		13.65KB	Share
CUV Notification of buy-back - CUV
14/03/24		13.06KB	Share
CUV CLINUVEL initiates on market share buy-back program
14/03/24	PRICE SENSITIVE	89.87KB	Share
CUV New case of SCENESSE efficacy in vitiligo presented at AAD
11/03/24	PRICE SENSITIVE	362.39KB	Share
CUV SCENESSE Presented at American Academy of Dermatology
08/03/24		74.91KB	Share
CUV Ceasing to be a substantial holder
05/03/24		1.12MB	Share
CUV SCENESSE provides photoprotection in variegate porphyria
04/03/24	PRICE SENSITIVE	195.58KB	Share
CUV Becoming a substantial holder
28/02/24		1.69MB	Share
CUV Final Director's Interest Notice
27/02/24		188.5KB	Share
CUV Half Year Results Webinar Recording
23/02/24		58.64KB	Share
CUV CLINUVEL Delivers Increased Revenues, Solid Earnings
22/02/24		107.14KB	Share
CUV CUV Appendix 4D Half Year Report
22/02/24	PRICE SENSITIVE	570.89KB	Share
CUV Director Resignation
21/02/24		67.94KB	Share
CUV CEO Letter to Shareholders
16/02/24		103.23KB	Share
CUV Half Year Results Investor Webinar
16/02/24		59.78KB	Share
CUV Change in substantial holding
31/01/24		1.58MB	Share
CUV CLINUVEL Newsletter 1 - January 2024
16/01/24		256.64KB	Share
CUV Chair Elect Letter
14/12/23		106.04KB	Share
CUV Change to Registered Office
07/12/23		129.35KB	Share
CUV Notification of cessation of securities - CUV
27/11/23		21.49KB	Share
CUV Change of Director's Interest Notice
27/11/23		526.02KB	Share
CUV Application for quotation of securities - CUV
27/11/23		25.55KB	Share
CUV CLINUVEL Newsletter V - November 2023
24/11/23		481.47KB	Share
CUV Sydney Vitiligo Presentation
10/11/23		874.94KB	Share
CUV Final Director's Interest Notice
02/11/23		190.98KB	Share
CUV CLINUVEL Appoints New Chair
31/10/23		135.75KB	Share
CUV Results of Meeting
31/10/23		276.04KB	Share
CUV CEO Presentation AGM
31/10/23		1.94MB	Share
CUV Chair's Address
31/10/23		160.97KB	Share
CUV CLINUVEL starts global Phase III vitiligo study
18/10/23		233.67KB	Share
CUV CLINUVEL Newsletter IV - October 2023
06/10/23		245.17KB	Share
CUV Board Changes after AGM
29/09/23		141.26KB	Share
CUV Notice of Annual General Meeting/Proxy Form
29/09/23		577.45KB	Share
CUV Change of Director's Interest Notice
20/09/23		321.36KB	Share
CUV CEO Letter to Shareholders
19/09/23		192.64KB	Share
CUV CLINUVEL Confirms AGM Date
13/09/23		117.29KB	Share
CUV CLINUVEL Vitiligo Expert Panel
12/09/23		217.38KB	Share
CUV SCENESSE in Adolescent EPP Study
05/09/23		228.91KB	Share
CUV CLINUVEL Investor Webinar Transcript
30/08/23		895.6KB	Share
CUV Appendix 4G and Corporate Governance Statement
29/08/23		579.18KB	Share
CUV CLINUVEL delivering increases in annual revenue, profit
29/08/23		271.69KB	Share
CUV Dividend/Distribution - CUV
29/08/23		22.38KB	Share
CUV Appendix 4E and Annual Report to Shareholders 2023
29/08/23	PRICE SENSITIVE	12.68MB	Share
CUV Annual Results Investor Webinar - time
28/08/23		131.05KB	Share
CUV Technical Note - CUV151 results DNA Damage
15/08/23		365.52KB	Share
CUV afamelanotide reduces DNA damage in healthy population
15/08/23		203.48KB	Share
CUV SCENESSE applied under 5 year US Veterans Affairs contract
26/07/23		140.08KB	Share
CUV CLINUVEL secures IP for melanocortins to treat CNS disorders
14/07/23		641.45KB	Share
CUV Notification regarding unquoted securities - CUV
30/06/23		25.38KB	Share
CUV Two Grounds of Appeal Upheld by NICE Panel
30/06/23		112.15KB	Share
CUV Notification of cessation of securities - CUV
29/06/23		21.48KB	Share
CUV Presentation - Melbourne Twilight Briefing
29/06/23		1.08MB	Share
CUV Change of Director's Interest Notice
28/06/23		313.22KB	Share
CUV CLINUVEL Newsletter III - June 2023
26/06/23		303.33KB	Share
CUV Strategic Update VI
01/06/23		1.84MB	Share
CUV PRENUMBRA administered to moderate & severe stroke patients
09/05/23		165.07KB	Share
CUV Expansion of global porphyria programs
01/05/23		136.22KB	Share
CUV CLINUVEL Newsletter II - April 2023
05/04/23		425.3KB	Share
CUV Investor Presentation - NYC Nasdaq Event
30/03/23		4.12MB	Share
CUV Technical Note - CUV803 Study and AIS
20/03/23		444.01KB	Share
CUV First stroke patient treated with PRENUMBRA Instant
20/03/23		271.53KB	Share
CUV DNA Repair data presented at AAD Meeting
17/03/23		119.77KB	Share
CUV Statement on Silicon Valley Bank
13/03/23		89.95KB	Share
CUV Proposed issue of securities - CUV
10/03/23		24.54KB	Share
CUV Commercial Update SCENESSE
09/03/23		127.84KB	Share
CUV Relief from Quarterly Reporting
02/03/23		82.33KB	Share
CUV CLINUVEL launches first dermatocosmetic product
01/03/23		254.92KB	Share
CUV Proposed issue of securities - CUV
28/02/23		24.53KB	Share
CUV Global SCENESSE demand drives increased revenues, earnings
24/02/23		165.94KB	Share
CUV CUV Appendix 4D Half Year Report
24/02/23	PRICE SENSITIVE	874.85KB	Share
CUV PRENUMBRA formulation completed for clinical trial use
15/02/23		257.84KB	Share
CUV Chair's Letter
09/02/23		215.25KB	Share
CUV Technical note - CUV151 results
02/02/23		370.66KB	Share
CUV Afamelanotide reduces UV skin damage in a healthy population
02/02/23		168.07KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	229.38KB	Share
CUV NEURACTHEL manufacturing processes advance
23/01/23		359.1KB	Share
CUV Technical Note - Xeroderma Pigmentosum
16/01/23		609.83KB	Share
CUV afamelanotide Reduces DNA Photodamage in XP
16/01/23		333.77KB	Share
CUV CLINUVEL Newsletter I - January 2023
10/01/23		510.39KB	Share
CUV CLINUVEL Newsletter VI - December 2022
23/12/22		246.06KB	Share
CUV Notification of cessation of securities - CUV
21/12/22		21.48KB	Share
CUV Presentation - Jefferies London Healthcare Conference
17/11/22		3.31MB	Share
CUV CLINUVEL Newsletter V - November 2022
09/11/22		546.94KB	Share
CUV Change of Director's Interest Notice
07/11/22		216.26KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
31/10/22	PRICE SENSITIVE	348.75KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.15		Change -0.070(0.57%)		Mkt cap ! $600.4M

Open	High	Low	Value	Volume
$12.22	$12.22	$11.93	$451.3K	37.54K

Buyers (Bids)

No.	Vol.	Price($)
4	211	$12.11

Sellers (Offers)

Price($)	Vol.	No.
$12.17	127	1

View Market Depth

No.	Vol.	Price($)
3	193	12.080
2	87	12.070
4	277	12.060
3	212	12.050
3	191	12.040

Price($)	Vol.	No.
12.130	162	4
12.140	56	2
12.150	147	3
12.160	43	1
12.170	44	1

Last trade - 11.40am 11/08/2025 (20 minute delay)


Last $12.20		Change -0.070 ( 0.26 %)
Open	High	Low	Volume
$12.05	$12.20	$11.95	2685
Last updated 11.55am 11/08/2025 ?

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories